ADAP News and Press, Adaptimmune Therapeutics plc From 11/08/23

2023-11-08 11:45:19 ET Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Dennis Williams – Senior ...

2023-11-08 07:37:08 ET More on Adaptimmune Adaptimmune: Spinning Sarcoma Into Gold Seeking Alpha’s Quant Rating on Adaptimmune Historical earnings data for Adaptimmune Financial information for Adaptimmune For further details see: Adaptimmu...

Candidate is 10x more sensitive to target peptide than competitor candidates Entry into the clinic in 2024 Selection of approaches from next-gen toolbox in development Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 8, 2023) - Adaptimmune Therapeutics plc (NAS...

2023-11-07 11:53:09 ET More on Adaptimmune Adaptimmune: Spinning Sarcoma Into Gold Seeking Alpha’s Quant Rating on Adaptimmune Historical earnings data for Adaptimmune Financial information for Adaptimmune For further details see: Adaptimmu...

40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review [2] ; primary efficacy endpoint requires 16/60 patients have responses Median duration of response was ~11 months, data are imm...

~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response of ~12 months ( CTOS 2022 ) Median overall survival (mOS) was ~17 months in SPEARHEAD-1 compared to historical mOS of <12 months for people with synovial sarcoma ...

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the third quarter ended September 30, 2023, befor...

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers 75% response rate in ovarian, urothelia...

2023-09-12 08:48:00 ET Summary Adaptimmune Therapeutics is a biotechnology company focused on developing cell therapies for solid tumors. Their afami-cel therapy has demonstrated signs of activity in patients with heavily pretreated sarcoma, with a 2-year rate of overall survival ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Devel...